Implementing Cytochrome P450 Pharmacogenomics in Clinical Practice: A Glimmer of Hope or Simply a Mirage?

Maslub, Mohammed Gamal Mohammed; Radwan, Mahasen Ali; Shaaban, Abubakar; Daud, Nur Aizati

doi:10.21608/erurj.2024.275758.1131

Implementing Cytochrome P450 Pharmacogenomics in Clinical Practice: A Glimmer of Hope or Simply a Mirage?

Document Type : Review article

Authors

¹ Clinical Pharmacy/ Pharmacy Practice Department, Faculty of Pharmacy, Egyptian Russian University, Cairo-Suez Road, Badr City, Cairo 11829, Egypt

² Division of Population Medicine, Cardiff University, Cardiff CF14 4YS, Wales, UK

³ School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Penang 11800, Malaysia

10.21608/erurj.2024.275758.1131

Abstract

Even though pharmacogenomics approaches are becoming progressively more advanced, opinions on their clinical validity and implementation remain controversial. To ascertain whether cytochrome P450 (CYPs) pharmacogenomics could be favorably implemented in healthcare settings, we reviewed the most recent research as part of this study. The Egyptian Knowledge Bank (EKB) online libraries of Elsevier, Wiley, Springer/Nature, and Sage were searched for a cumulative period that began on January 1, 2015, and ended on December 31, 2023. Priority was given to articles highlighting the application of CYP pharmacogenomics in clinical practice. Six hundred thirteen articles were initially found after an exhaustive search. Based on the inclusion criteria, 26 articles were included. Findings revealed that pharmacogenomics could optimize specific medication prescriptions and reduce potential drug-related problems like the case of tacrolimus. However, more large-scale research could help implement pharmacogenetics testing in practice settings regarding other medications, such as statins. By implementing pharmacogenomics in healthcare, clinicians can access pharmacogenomic data through web-based technologies. Pharmacogenomics advancements save time and help rationalize medication use depending on the patient’s genotype. Our research showed that more pharmacogenomics research is necessary to fully understand the relationship between the presence of genetic variants in CYPs and medication metabolism and response.

Keywords